OncoMatch/Clinical Trials/NCT05377996
A Study of XMT-1660 in Participants With Solid Tumors
Is NCT05377996 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies XMT-1660 for triple negative breast cancer.
Treatment: XMT-1660 — A Study of XMT-1660 in Solid Tumors
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Triple-Negative Breast Cancer
Breast Carcinoma
Endometrial Cancer
Ovarian Cancer
Head and Neck Squamous Cell Carcinoma
Biomarker criteria
Excluded: VTCN1 prior B7-H4 targeted treatment
Prior B7-H4 targeted treatment
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: antibody-drug conjugate
Exception: Prior treatment with another ADC containing other payloads is allowed
Prior treatment with an Antibody Drug Conjugate (ADC) containing an auristatin payload
Cannot have received: B7-H4 targeted therapy
Prior B7-H4 targeted treatment
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Mayo Clinic Comprehensive Cancer Center · Phoenix, Arizona
- UC Irvine Health-Chao Family Comprehensive Cancer Center · Orange, California
- UCSF Helen Diller Family Comprehensive Cancer Center · San Francisco, California
- UCLA · Santa Monica, California
- Mayo Clinic - Jacksonville · Jacksonville, Florida
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT05377996 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior antibody-drug conjugate, B7-H4 targeted therapy disqualifies patients from enrollment.
Are patients with VTCN1 alterations eligible?
No. VTCN1 prior B7-H4 targeted treatment is an exclusion criterion.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify